Epizyme, Inc.: Series B $8M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Jan

2010

Epizyme, Inc.: Series B $32M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Oct

2009

Constellation Pharmaceuticals, Inc. Series B $17.2M

Posted in I - Series B, Q - 3Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, XX - MA

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $17.2M Series B financing. Participants include Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Nov

2008

Constellation Pharmaceuticals: Series A $32M

Posted in I - Series A, Q - 2Q08, R - NORTH EAST, X - Epigenetics

Constellation Pharmaceuticals (Cambridge, MA) development-stage biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epgenetic function, closed a $32M Series A financing. Participants include Third Rock Ventures, Column Group, and Venrock

to top of page...